Lifeline Biotechnologies, Inc. Retains Merchant Banking Services Firm

Lifeline Biotechnologies, Inc. (Pink Sheets:LLBO) today announced it has retained Brass Bulls, merchant banking firm, to provide the Company with professional services including public relations, corporate finance, merger acquisition and business consultation to assist in achieving Lifeline’s corporate goals.

“We are very pleased and look forward to Brass Bulls assisting us, amongst other services, in our search for a strategic partner. The focus will be on building shareholder value and spreading risk. Meantime, our focus is to bring our First Warning System, a process that is designed to assist in the early detection of breast cancer, to market. Our immediate objective is the preparation and submission of a 510(k) application to the FDA for clearance,” stated Jim Holmes, CEO of Lifeline Biotechnologies.

Paul Lovito, President of Brass Bulls, stated, “Lifeline has spent over 20 years developing the First Warning System and is now at the final phase towards going to market. The Company is at a critical point in its corporate finance, marketing and public relations needs. We look forward to assisting the Company in building its shareholder value through increased market exposure, corporate transparency and strategic alliances.”

Lifeline Biotechnologies has in the past year filed for a patent on the recent technological advancements of the First Warning System™, which has achieved the robust capability of identifying and classifying abnormalities of the breast with sensitivities of 95% to 100% and specificities of 87% to 90%. Currently, it is a well known fact that mammograms are missing an estimated 30 to 40% of the breast cancers.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing, successful development of the Company’s product and regulatory and shareholder approval for anticipated actions.